AcquisitionsJul 28, 2026, 07:02 AM
Repligen to Acquire BioLife Solutions; Q2 Revenue $204M, FY26 EPS Guidance Raised
AI Summary
Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, a strategic move expected to enhance its cell therapy leadership and be accretive to revenue growth, margin, and adjusted EPS. Concurrently, the company reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 13% organic year-over-year increase, and adjusted operating income growing by 55%. Based on these strong results and improved outlook, Repligen raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09.
Key Highlights
- Definitive agreement to acquire BioLife Solutions announced.
- Q2 2026 revenue of $204 million, +13% organic year-over-year.
- Q2 2026 adjusted operating income increased 55% year-over-year.
- Q2 2026 adjusted EPS was $0.54.
- Raised FY26 organic revenue growth guidance to 10.5%-13.5%.
- Raised FY26 adjusted EPS guidance to $2.03-$2.09.
- Opened new Repligen Training & Innovation Center in the Netherlands.
- Cash, cash equivalents, and marketable securities totaled $810 million.
Price Impact
More from RGEN